Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol’s Plavix woes continue

Executive Summary

Bristol-Myers Squibb has received a subpoena from the New York Attorney General's office for documents relating to its settlement with Apotex over Plavix (clopidogrel), the company announces April 26. The proposed deal, which was denied antitrust clearance by the Federal Trade Commission, is also being investigated by the Department of Justice (1"The Pink Sheet" Aug. 7, 2006, p. 9). In addition, the company announces April 26 that it has received a Civil Investigative Demand by the FTC requesting documents related to the proposed settlement. Bristol maintains that it is impossible at this time to assess the impact of the investigations, if any, on the company's compliance with the Deferred Prosecution Agreement with the United States Attorney's Office for the District of New Jersey. The deferred prosecution agreement is part of a 2004 settlement Bristol entered into with the SEC and DOJ over allegations of "channel stuffing," under which the company has two years to comply with all terms of the settlement or face prosecution (2"The Pink Sheet" June 20, 2005, p. 17)...

You may also be interested in...



Bristol $300 Mil. DoJ Settlement Includes Separation OF CEO/Chairman Roles

Bristol-Myers Squibb board member James Robinson will take on additional corporate governance oversight responsibilities, including meeting with execs prior to analyst calls, as the newly-appointed chairman

Health And Wellness Trademark Review 18 February, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Genfit Delays NASH Data While It Confers With US FDA On Methodology

Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.

UsernamePublicRestriction

Register

PS048299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel